Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Harvey Preisler
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Anatomy
Chemicals & Drugs
Procedures
Physiology
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
58
Raza, Azra
24
Browman, George
21
Goldberg, Jack
20
Venugopal, Parameswaran
11
Li, B
11
Gregory, Stephanie
10
Coon, John
9
Kotelnikov, VM
9
Mundle, Suneel
9
Panje, WR
8
Nayini, Jaya
8
Silvestri, F
8
Caldarelli, DD
7
Sivaraman, Smitha
7
Hutchinson, J
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Harvey Preisler (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2003: Gladstone Betty; Sivaraman Smitha; Galili Naomi; Venugopal Parameswaran; Janssen Imke; Nayini Jaya; Yang Jie; Hsu Wei-Tong; Raza Azra; Preisler Harvey D
A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH.
Leukemia research 2003;27(6):529-37.
-
2003: Huang X K; Meyer P; Li B; Raza A; Preisler H D
The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro.
Leukemia & lymphoma 2003;44(1):157-64.
-
2002: Coon John S; Marcus Elizabeth; Gupta-Burt Shalina; Seelig Steven; Jacobson Kris; Chen Shande; Renta Vivian; Fronda Geraldo; Preisler Harvey D
Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1061-7.
-
2002: Kuropkat Christiane; Venkatesan T K; Caldarelli D D; Panje W R; Hutchinson J; Preisler H D; Coon J S; Werner J A
Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx.
Auris, nasus, larynx 2002;29(2):165-74.
-
2001: Preisler H D; Li B; Chen H; Fisher L; Nayini J; Raza A; Creech S; Venugopal P
P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(10):1589-95.
-
2001: Preisler H D; Perambakam S; Li B; Hsu W T; Venugopal P; Creech S; Sivaraman S; Tanaka N
Alterations in IRF1/IRF2 expression in acute myelogenous leukemia.
American journal of hematology 2001;68(1):23-31.
-
2001: Devemy E; Li B; Tao M; Horvath E; Chopra H; Fisher L; Nayini J; Creech S; Venugopal P; Yang J; Kaspar C; Hsu W; Preisler H D
Poor prognosis acute myelogenous leukemia: 3--biological and molecular biological changes during remission induction therapy.
Leukemia research 2001;25(9):783-91.
-
2001: Galili U; Chen Z C; Manches O; Plumas J; Preisler H
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Journal of hematotherapy & stem cell research 2001;10(4):501-11.
-
2001: Preisler H D; Venugopal P; Gregory S A; Adler S; Gezer S; Hsu W T; Manson S; Larson A; Jajeh A; Slvinick D; Galvez A
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
Leukemia & lymphoma 2001;41(3-4):333-6.
-
2001: Tao M; Li B; Nayini J; Sivaraman S; Song S; Larson A; Toofanfard M; Chen H; Venugopal P; Preisler H D
In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia.
Leukemia & lymphoma 2001;41(1-2):161-8.
-
2001: Enschede S H; Shahidi H; Venugopal P; Riley M B; Huang R; Jajeh A; Preisler H D; Gregory S A
Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
Leukemia & lymphoma 2001;40(3-4):325-34.
-
2001: Venugopal P; Manson S; Preisler H D
Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.
Cancer treatment and research 2001;108():257-65.
-
2001: Preisler H D
Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML.
Cancer treatment and research 2001;108():185-230.
-
2001: Perambakam S; Li B; Preisler H
Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia.
Cancer investigation 2001;19(4):346-51.
-
2000: Li B; Yang J; Tao M; Nayini J; Horvath E; Chopra H; Meyer P; Venugopal P; Preisler H D
Poor prognosis acute myelogenous leukemia 2--biological and molecular biological characteristics and treatment outcome.
Leukemia research 2000;24(9):777-89.
-
2000: Preisler H D; Venugopal P; Gregory S A; Hsu W; Loew J; Adler S; Gezer S; Creech S; Galvez A; Slivnick D; Andric T; Larson R A; Jajeh A
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine).
Leukemia research 2000;24(8):671-80.
-
2000: Sivaraman S; Deshpande C G; Ranganathan R; Huang X; Jajeh A; O'Brien T; Huang R W; Gregory S A; Venugopal P; Preisler H D
Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha?
Microscopy research and technique 2000;50(3):251-7.
-
2000: Bi S; Gao X; Devemy E; Chopra H; Venugopal P; Raza A; Preisler H D
Cytokine production by in vitro processed and unprocessed haematopoietic cells.
Cytokine 2000;12(7):1124-8.
-
2000: Sivaraman S; Venugopal P; Ranganathan R; Deshpande C G; Huang X; Jajeh A; Gregory S A; O'Brien T; Preisler H D
Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia.
Cytokines, cellular & molecular therapy 2000;6(2):81-7.
-
2000: Tao M; Li B; Nayini J; Andrews C B; Huang R W; Devemy E; Song S; Venugopal P; Preisler H D
SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients.
Cytokine 2000;12(6):699-707.
-
2000: Mundle S D; Mativi B Y; Cartlidge J D; Dangerfield B; Broady-Robinson L; Li B; Shetty V; Venugopal P; Gregory S A; Preisler H D; Raza A
Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1.
British journal of haematology 2000;109(2):376-81.
-
2000: Venugopal P; Sivaraman S; Huang X K; Nayini J; Gregory S A; Preisler H D
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia.
Leukemia research 2000;24(5):411-5.
-
2000: Preisler H D; Li B; Yang B L; Huang R W; Devemy E; Venugopal P; Tao M; Chopra H; Gregory S A; Adler S; Sivaraman S; Toofanfard P; Jajeh A; Galvez A; Robin E
Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):807-12.
-
2000: Li B; Yang J; Andrews C; Chen Y X; Toofanfard P; Huang R W; Horvath E; Chopra H; Raza A; Preisler H D
Telomerase activity in preleukemia and acute myelogenous leukemia.
Leukemia & lymphoma 2000;36(5-6):579-87.
-
1999: Preisler H D; Gao X Z; Ming T; Li B; Bi S; Devemy E; Loew J; Raza A
Marrow cytokine transcripts and the secondary hematologic disorders.
Leukemia & lymphoma 1999;35(3-4):297-302.
-
1999: Preisler H D; Kauffman S
A proposal regarding the mechanism which underlies lineage choice during hematopoietic differentiation.
Leukemia research 1999;23(8):685-94.
-
1999: Yang J; Li B R; Nayini J; Venugopal P; Tao M; Andres C B; Preisler H D
Tyrosine phosphorylation of Shc proteins in normal CD34+ progenitor cells and leukemic cells.
Blood 1999;94(1):373-4.
-
1999: Mundle S; Venugopal P; Shetty V; Ali A; Chopra H; Handa H; Rose S; Mativi B Y; Gregory S A; Preisler H D; Raza A
The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows.
International journal of hematology 1999;69(3):152-9.
-
1999: Preisler H D
Fitness landscapes and the myeloid leukemias.
Leukemia research 1999;23(2):167-76.
-
1998: Hsu W T; Preisler H; Szego K; Sprudzs R; Gao X Z
The ABL/BCR fusion gene on chromosome 9 in Ph-negative chronic myelogenous leukemia: a case for vigilance in fluorescence in situ hybridization interpretation.
Cancer genetics and cytogenetics 1998;104(1):57-60.
-
1998: Gao X Z; Bi S; Copra H; Devemy E; Venugopal P; Li B; Hsu W T; Loew J; Galvez A; Gregory S; Yang J; Horvath E; Preisler H D
Cytokine gene activity in AML cells in vivo in patients.
Leukemia research 1998;22(5):429-38.
-
1998: Whisler L C; Wood N B; Caldarelli D D; Hutchinson J C; Panje W R; Friedman M; Preisler H D; Leurgans S; Nowak J; Coon J S
Regulators of proliferation and apoptosis in carcinoma of the larynx.
The Laryngoscope 1998;108(5):630-8.
-
1998: Hegde P U; Brenski A C; Caldarelli D D; Hutchinson J; Panje W R; Wood N B; Leurgans S; Preisler H D; Taylor S G; Caldarelli L; Coon J S
Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer.
Archives of otolaryngology--head & neck surgery 1998;124(1):80-5.
-
1997: Handa H; Hegde U P; Kotelnikov V M; Mundle S D; Dong L M; Burke P; Rose S; Hsu W T; Gaskin F; Raza A; Preisler H D
The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients.
Leukemia research 1997;21(11-12):1087-96.
-
1997: Handa H; Hegde U P; Kotelnikov V M; Mundle S D; Dong L M; Burke P; Rose S; Gaskin F; Raza A; Preisler H D
Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.
Leukemia research 1997;21(6):479-89.
-
1997: Wood N B; Kotelnikov V; Caldarelli D D; Hutchinson J; Panje W R; Hegde P; Leurgans S; LaFollette S; Taylor S G; Preisler H D; Coon J S
Mutation of p53 in squamous cell cancer of the head and neck: relationship to tumor cell proliferation.
The Laryngoscope 1997;107(6):827-33.
-
1997: Kotelnikov V; Cass L; Coon J S; Spaulding D; Preisler H D
Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):669-73.
-
1997: Kotelnikov V M; Coon J S; Mundle S; Kelanic S; LaFollette S; Taylor S I V; Hutchinson J; Panje W; Caldarelli D D; Preisler H D
Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):95-101.
-
1997: Preisler H D; Raza A; Bonomi P; Taylor S; LaFolette S; Leslie W; Lincoln S
Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases.
Cancer investigation 1997;15(4):358-68.
-
1996: Kotelnikov V M; Coon J S; Taylor S; Hutchinson J; Panje W; Caldareill D D; LaFollette S; Preisler H D
Proliferation of epithelia of noninvolved mucosa in patients with head and neck cancer.
Head & neck 1996;18(6):522-8.
-
1996: Raza A; Mundle S; Shetty V; Alvi S; Chopra H; Span L; Parcharidou A; Dar S; Venugopal P; Borok R; Gezer S; Showel J; Loew J; Robin E; Rifkin S; Alston D; Hernandez B; Shah R; Kaizer H; Gregory S; Preisler H
A paradigm shift in myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1648-52.
-
1996: Preisler H D; Kotelnikov V M; LaFollette S; Taylor S; Mundle S; Wood N; Coon J S; Hutchinson J; Panje W; Caldarelli D D; Griem K
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(9):1453-60.
-
1996: Hegde U; Kotelnikov V M; Handa H; Burke P; Preisler H D
Accuracy of immunohistochemistry and flow cytometry in estimating the proportion of leukemic cells in S phase in chronic myeloid leukemia patients.
Leukemia & lymphoma 1996;22(5-6):431-7.
-
1996: Mundle S D; Gregory S A; Preisler H D; Raza A
Enzymatic programming of apoptotic cell death.
Pathobiology : journal of immunopathology, molecular and cellular biology 1996;64(3):161-70.
-
1995: Preisler H D; Raza A; Gopal V; Ahmad S; Bokhari J
Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia.
Leukemia research 1995;19(10):693-8.
-
1995: Mundle S D; Gao X Z; Khan S; Gregory S A; Preisler H D; Raza A
Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro.
Anticancer research 1995;15(5B):1895-904.
-
1995: Kotelnikov V M; Coon J S; Taylor S; Hutchinson J; Panje W; Caldarelli D D; LaFollette S; Preisler H D
In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region.
Cell proliferation 1995;28(9):497-509.
-
1995: Preisler H D; Venugopal P
Regrowth resistance in cancer: why has it been largely ignored?
Cell proliferation 1995;28(6):347-56.
-
1995: Kotelnikov V M; Coon JS I V; Haleem A; Taylor S I V; Hutchinson J; Panje W; Caldarelli D D; Griem K; Preisler H D
Cell kinetics of head and neck cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(5):527-37.
-
1994: Preisler H D; Raza A; Larson R; Goldberg J; Tricot G; Browman G; Bennett J
The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.
Leukemia & lymphoma 1994;14(3-4):273-8.
-
1994: Preisler H D; Raza A; Gopal V; Banavali S D; Bokhari J; Lampkin B
The study of acute leukemia cells by means of acridine orange staining and flow cytometry.
Leukemia & lymphoma 1994;13(1-2):61-73.
-
1994: Preisler H D; Banavali S D; Yin M; Venu G; Li Y Q; Gaskins F; Raza A
Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1511-6.
-
1993: Silvestri F; Banavali S; Savignano C; Preisler H D; Baccarani M
CD34+ cell selection: focus on immunomagnetic beads and chymopapain.
The International journal of artificial organs 1993;16 Suppl 5():96-101.
-
1993: Goldberg J; Gryn J; Raza A; Bennett J; Browman G; Bryant J; Grunwald H; Larson R; Vogler R; Preisler H
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
American journal of hematology 1993;43(4):286-90.
-
1993: Preisler H; Larson R; Banavali S; Yin M; Li Y Q; Banerjee M; Gopal V; Raza A
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.
Leukemia & lymphoma 1993;10(3):183-6.
-
1993: Raza A; Preisler H D; Browman G P; Larson R A; Rustum Y M; Goldberg J; Vogler R; Miller K A; Bennett J; Kukla C
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
Leukemia & lymphoma 1993;10(1-2):57-66.
-
1993: Kadam P; Steele P; Li Y Q; Preisler H
Analysis of the c-myc and N-ras genes in acute myelogenous leukemia cells which manifest the constitutive expression of the c-myc gene.
Anticancer research 1993;13(3):747-51.
-
1993: Raza A; Preisler H D; Li Y Q; Larson R A; Goldberg J; Browman G; Bennett J; Grunwald H; Vogler R; Kukla C
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia.
American journal of hematology 1993;42(4):359-66.
-
1993: Raza A; Preisler H; Lampkin B; Lykins J; Kukla C; Gartside P; Sheikh Y; Yousuf N; White M; Barcos M
Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia.
American journal of hematology 1993;42(2):147-57.
-
1993: Banavali S D; Pancoast J R; Tricot G; Larson R; Goldberg J; Raza A; Bismayer J A; Preisler H D
The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1162-7.
-
1993: Preisler H; Raza A
An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system.
Leukemia & lymphoma 1993;11 Suppl 1():145-50.
-
1993: Yin M; Silvestri F F; Banavali S D; Gopal V; Hulette B C; Kuvelkar R B; Young A N; Mayers G; Preisler H D
Clonogenic potential of myeloid leukaemia cells in vitro is restricted to leukaemia cells expressing the CD34 antigen.
European journal of cancer (Oxford, England : 1990) 1993;29A(16):2279-83.
-
1992: Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler H D
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
Experimental hematology 1992;20(10):1194-200.
-
1992: Preisler H D; Raza A; Larson R A
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.
Blood 1992;80(10):2600-3.
-
1992: Silvestri F; Banavali S; Yin M; Gopal V; Baccarani M; Preisler H D
Comparison of two methods for concentrating CD34+ cells from patients with acute non-lymphocytic leukemia.
Leukemia & lymphoma 1992;8(4-5):389-96.
-
1992: Gopal V; Hulette B; Li Y Q; Kuvelkar R; Raza A; Larson R; Goldberg J; Tricot G; Bennett J; Preisler H
c-myc and c-myb expression in acute myelogenous leukemia.
Leukemia research 1992;16(10):1003-11.
-
1992: Yin M; Gopal V; Banavali S; Gartside P; Preisler H
Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(9):898-901.
-
1992: Preisler H D; Gopal V; Banavali S D; Finke D; Bokari S A
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents.
Cancer research 1992;52(15):4090-5.
-
1992: Silvestri F; Banavali S; Yin M; Gopal V; Savignano C; Baccarani M; Preisler H D
CD34-positive cell selection by immunomagnetic beads and chymopapain.
Haematologica 1992;77(4):307-10.
-
1992: Silvestri F; Banavali S; Baccarani M; Preisler H D
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications.
Haematologica 1992;77(3):265-73.
-
1992: Pavelic Z P; Pavelic L; Lower E E; Gapany M; Gapany S; Barker E A; Preisler H D
c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.
Cancer research 1992;52(9):2597-602.
-
1992: Raza A; Yousuf N; Bokhari S A; Mehdi A; Masterson M; Lampkin B; Yanik G; Mazewski C; Khan S; Preisler H
Contribution of in vivo proliferation/differentiation studies toward the development of a combined functional and morphologic system of classification of neoplastic diseases.
Cancer 1992;69(6 Suppl):1557-66.
-
1992: Preisler H D; Raza A
The role of emerging technologies in the diagnosis and staging of neoplastic diseases.
Cancer 1992;69(6 Suppl):1520-6.
-
1992: Preisler H D; Raza A
Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():81-4.
-
1992: Hulette B C; Banavali S D; Finke D P; Gopal V; Preisler H D
Protooncogene expression in subpopulations of cells from leukemia patients.
Cytometry 1992;13(6):653-8.
-
1992: Li Y Q; Gopal V; Kadam P; Files S; Preisler H
The multiple drug resistance gene, MDR1: expression at the protein and RNA levels.
Medical oncology and tumor pharmacotherapy 1992;9(1):3-9.
-
1992: Gopal V; Kadam P; Preisler H; Hulette B; Li Y Q; Steele P; Freeman J; Banavali S
Abnormal regulation of the myc gene in myeloid leukemia.
Medical oncology and tumor pharmacotherapy 1992;9(3):139-47.
-
1991: Banavali S D; Silvestri F F; Pavelic K; Pavelic Z P; Smith P L; Preisler H D
Studies of the geographic patterns of c-myc expression in bone marrow.
Cell proliferation 1991;24(6):529-42.
-
1991: Preisler H D; Larson R A; Raza A; Browman G; Goldberg J; Vogler R; Day R; Gottlieb A; Vardiman J W; Bennett J
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure.
British journal of haematology 1991;79(3):390-7.
-
1991: Raza A; Preisler H; Lampkin B; Yousuf N; Tucker C; Peters N; White M; Kukla C; Gartside P; Siegrist C
Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia.
British journal of haematology 1991;79(1):33-9.
-
1991: Silvestri F F; Banavali S D; Hulette B C; Civin C I; Preisler H D
Isolation and characterization of the CD34+ hematopoietic progenitor cells from the peripheral blood of patients with chronic myeloid leukemia.
International journal of cell cloning 1991;9(5):474-90.
-
1991: Preisler H D; Raza A; Kukla C; Larson R; Goldberg J; Browman G
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia.
Blood 1991;78(3):849-50.
-
1991: Gao X Z; Yin M Y; Wang Z Q; Raza A; Preisler H D
Effects of rGM-CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA.
Cell biochemistry and function 1991;9(3):155-61.
-
1991: Pavelic Z P; Steele P; Preisler H D
Evaluation of c-myc proto-oncogene in primary human breast carcinomas.
Anticancer research 1991;11(4):1421-7.
-
1991: Yin M Y; Gao X Z; Wang Z Q; Preisler H D
Studies of the proliferation and differentiation of immature myeloid cells in vitro: 4: Preculture proto-oncogene expression and the behaviour of myeloid leukemia cells in vitro.
Cell biochemistry and function 1991;9(1):39-47.
-
1991: Preisler H; Raza A; Larson R; Goldberg J; Tricot G; Carey M; Kukla C
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.
Leukemia research 1991;15(9):773-80.
-
1991: Banavali S; Silvestri F; Hulette B; Hurtubise P; Srivastava A; Civin C I; Preisler H D
Expression of hematopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia.
Leukemia research 1991;15(7):603-8.
-
1990: Raza A; Preisler H D; Day R; Yasin Z; White M; Lykins J; Kukla C; Barcos M; Bennett J; Browman G
Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.
Blood 1990;76(11):2191-7.
-
1990: Sato H; Preisler H; Day R; Raza A; Larson R; Browman G; Goldberg J; Vogler R; Grunwald H; Gottlieb A
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.
British journal of haematology 1990;75(3):340-5.
-
1990: Baer M R; Sreekantaiah C; Jani Sait S N; Sawyer A M; Block A; Sandberg A A; Preisler H D
Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(4):297-301.
-
1990: Wang Z Q; Yin M Y; Xie X X; Yang P M; Sato H; Mayers G; Riobowal C; Preisler H D
Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cells.
European journal of cancer (Oxford, England : 1990) 1990;26(6):694-8.
-
1990: Raza A; Preisler H D
Cellular dynamics of leukemias.
Critical reviews in oncogenesis 1990;1(4):373-88.
-
1989: Gao X Z; Yin M Y; Preisler H D
The effects of cytosine arabinoside and GM-CSF in leukemic cells in vitro.
Anticancer research 1989;9(4):1053-5.
-
1989: Baer M R; Barcos M; Farrell H; Raza A; Preisler H D
Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986.
Cancer 1989;63(11):2192-200.
-
1989: Browman G; Preisler H; Raza A; Syracuse K; Azarnia N; Benger A; Chervenick P; D'Arrigo P; Doeblin T; Goldberg J
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
British journal of haematology 1989;71(4):493-7.
-
1989: Preisler H D; Anderson K; Rai K; Cuttner J; Yates J; DuPre E; Holland J F
The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years.
British journal of haematology 1989;71(2):189-94.
-
1989: Preisler H D; Raza A; Larson R; LeBeau M; Browman G; Goldberg J; Grunwald H; Volger R; Verkh L; Singh P
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
Blood 1989;73(1):255-62.
-
1989: Raza A; Khan S P; Mehdi I; Imren S; Yasin Z; Preisler H D
Cell cycle characteristics in myeloid leukemias.
Bone marrow transplantation 1989;4 Suppl 1():26-9.
-
1989: Baer M R; Gao X Z; Sato H; Singh P; Preisler H D
Proto-oncogene expression during early myeloid differentiation of normal peripheral blood progenitor cells.
Leukemia research 1989;13(2):165-72.
-
1989: Raza A; Gezer S; Mehdi I; Preisler H D
Detection of BrdU in the regenerating bone marrow cells of a patient with AML.
Leukemia research 1989;13(12):1055-9.
-
1988: Kaufman D C; Baer M R; Gao X Z; Wang Z Q; Preisler H D
Enhanced expression of the granulocyte-macrophage colony stimulating factor gene in acute myelocytic leukemia cells following in vitro blast cell enrichment.
Blood 1988;72(4):1329-32.
-
1988: Preisler H D
A hypothesis regarding the development of acute myeloid leukemia from preleukemic disorders. The role of protooncogenes.
Cancer genetics and cytogenetics 1988;32(1):133-42.
-
1988: Baer M R; Gao X Z; Preisler H D
Sustained viability of acute myelogenous leukemia cells in liquid suspension culture correlates with occurrence of differentiation.
Leukemia research 1988;12(8):647-50.
-
1988: Preisler H D; Sato H; Yang P M; Wilson M; Kaufman C; Watt R
Assessment of c-myc expression in individual leukemic cells.
Leukemia research 1988;12(6):507-16.
-
1987: Barcos M; Lane W; Gomez G A; Han T; Freeman A; Preisler H; Henderson E
An autopsy study of 1206 acute and chronic leukemias (1958 to 1982).
Cancer 1987;60(4):827-37.
-
1987: Preisler H D
The treatment of acute non-lymphocytic leukemia.
Blood reviews 1987;1(2):97-105.
-
1987: Swartwout S G; Preisler H; Guan W D; Kinniburgh A J
Relatively stable population of c-myc RNA that lacks long poly(A).
Molecular and cellular biology 1987;7(6):2052-8.
-
1987: Preisler H D; Raza A; Early A; Kirshner J; Brecher M; Freeman A; Rustum Y; Azarnia N; Priore R; Sandberg A
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(5):722-30.
-
1987: Preisler H D; Raza A; Barcos M; Azarnia N; Larson R; Walker I; Browman M; Grunwald H; D'Arrigo P; Doeblin T
High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):75-82.
-
1987: Preisler H D; Rustum Y M; Azarnia N; Priore R
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Cancer chemotherapy and pharmacology 1987;19(1):69-74.
-
1987: Gessner T; Preisler H D; Azarnia N; Bolanowska W; Vogler W R; Grunwald H; Joyce R; Goldberg J
Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.
Medical oncology and tumor pharmacotherapy 1987;4(1):23-31.
-
1987: Raza A; Maheshwari Y; Yasin Z; Mandava N; Mayers G; Preisler H D
A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.
Leukemia research 1987;11(12):1079-87.
-
1987: Rai K R; Cuttner J; Holland J F; Davis R; Mayer R; McIntyre O R; Preisler H; Yates J
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.
Haematology and blood transfusion 1987;30():31-4.
-
1987: Raza A; Maheshwari Y; Ucar K; Mayers G; Preisler H D
Proliferative characteristics of acute nonlymphocytic leukemia in vivo.
Acta haematologica 1987;77(3):140-5.
-
1987: Preisler H D; Guan W D; Khan S; Kinniburgh A
Differing patterns of proto-oncogene expression in immature and mature myeloid cells.
Leukemia research 1987;11(10):923-34.
-
1986: Preisler H D; Raza A; Barcos M; Azarnia N; Larson R; Browman G; Walker I; Grunwald H; D'Arrigo P; Stein A
High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study.
American journal of hematology 1986;23(2):131-4.
-
1986: Preisler H D; Priore R; Azarnia N; Barcos M; Raza A; Rakowski I; Vogler R; Winton E L; Browman G; Goldberg J
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements.
British journal of haematology 1986;63(4):625-36.
-
1986: Vogler W R; Preisler H D; Winton E F; Gottlieb A J; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller K B
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Cancer treatment reports 1986;70(4):455-9.
-
1986: Preisler H D; Raza A; Larson R; Browman G; Goldberg J; Grunwald H; Vogler R; Bennett J; Gottlieb A; D'Arrigo P
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia.
Cancer chemotherapy and pharmacology 1986;18(3):257-60.
-
1985: Caligiuri M A; Early A P; Marinello M J; Preisler H D
Acute nonlymphocytic leukemia in a glue sniffer.
American journal of hematology 1985;20(1):89-90.
-
1985: Raza A; Ucar K; Preisler H D; Mayers G
In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
Seminars in oncology 1985;12(2 Suppl 3):9-19.
-
1985: Raza A; Spiridonidis C; Ucar K; Mayers G; Bankert R; Preisler H D
Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA-specific probe.
Cancer research 1985;45(5):2283-7.
-
1985: Preisler H D; Raza A; Azarnia N; Rakowsky I; Barcos M; Browman G; Booker L; Goldberg J; Gottleib A; Brennan J
Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy.
European journal of cancer & clinical oncology 1985;21(5):563-71.
-
1985: Benger A; Browman G P; Walker I R; Preisler H D
Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report.
Cancer treatment reports 1985;69(2):240-1.
-
1984: Raza A; Minowada J; Barcos M; Rakowski I; Preisler H D
Ph1-positive acute leukemia.
European journal of cancer & clinical oncology 1984;20(12):1509-16.
-
1984: Preisler H D; Epstein J; Barcos M; Priore R; Raza A; Browman G P; Vogler R; Winton E; Grunwald H; Rai K
Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
British journal of haematology 1984;58(1):19-32.
-
1984: Preisler H D; Epstein J; Raza A; Azarnia N; Browman G; Booker L; Goldberg J; Gottlieb A; Brennan J; Grunwald H
Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.
European journal of cancer & clinical oncology 1984;20(8):1061-8.
-
1984: Raza A; Preisler H D; Mayers G L; Bankert R
Rapid enumeration of S-phase cells by means of monoclonal antibodies.
The New England journal of medicine 1984;310(15):991.
-
1984: Preisler H D; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
British journal of haematology 1984;56(3):399-407.
-
1984: Preisler H D; Gessner T; Azarnia N; Bolanowska W; Epstein J; Early A P; D'Arrigo P; Vogler R; Winton L; Chervenik P
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia.
Cancer chemotherapy and pharmacology 1984;12(2):125-30.
-
1983: Browman G; Goldberg J; Gottlieb A J; Preisler H D; Azarnia N; Priore R L; Brennan J K; Vogler W R; Winton E F; Miller K B
The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia.
American journal of hematology 1983;15(3):227-35.
-
1983: Preisler H D; Early A P; Raza A; Vlahides G; Marinello M J; Stein A M; Browman G
Therapy of secondary acute nonlymphocytic leukemia with cytarabine.
The New England journal of medicine 1983;308(1):21-3.
-
1983: Bolanowska W; Gessner T; Preisler H
A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.
Cancer chemotherapy and pharmacology 1983;10(3):187-91.
-
1983: Preisler H; Barcos M; Reese P; Priore R L; Pothier L
Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.
Leukemia research 1983;7(1):67-75.
-
1982: Preisler H D; Brecher M; Browman G; Early A P; Walker I R; Raza A; Freeman A
The treatment of acute myelocytic leukemia in patients 30 years of age and younger.
American journal of hematology 1982;13(3):189-98.
-
1982: Early A P; Preisler H D; Higby D J; Brecher M; Browman G; McBride J A
High-dose cytosine arabinoside: clinical response to therapy in acute leukemia.
Medical and pediatric oncology 1982;10 Suppl 1():239-50.
-
1981: Rai K R; Holland J F; Glidewell O J; Weinberg V; Brunner K; Obrecht J P; Preisler H D; Nawabi I W; Prager D; Carey R W; Cooper M R; Haurani F; Hutchison J L; Silver R T; Falkson G; Wiernik P; Hoagland H C; Bloomfield C D; James G W; Gottlieb A; Ramanan S V; Blom J; Nissen N I; Bank A; Ellison R R; Kung F; Henry P; McIntyre O R; Kaan S K
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Blood 1981;58(6):1203-12.
Sign-in to see more
